{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T21:14:58Z","timestamp":1783199698700,"version":"3.54.6"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Minerva Pharmaceuticals"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.schres.2019.08.029","type":"journal-article","created":{"date-parts":[[2019,9,2]],"date-time":"2019-09-02T07:28:20Z","timestamp":1567409300000},"page":"352-356","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Effects of Roluperidone (MIN-101) on two dimensions of the negative symptoms factor score: Reduced emotional experience and reduced emotional expression"],"prefix":"10.1016","volume":"215","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9501-9366","authenticated-orcid":false,"given":"Philip D.","family":"Harvey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay B.","family":"Saoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remy","family":"Luthringer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Moroz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuliya","family":"Blazhevych","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristinel","family":"Stefanescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2019.08.029_bb0005","doi-asserted-by":"crossref","first-page":"7160","DOI":"10.1073\/pnas.1705154114","article-title":"Identification of the gene that codes for the sigma-2 receptor","volume":"14","author":"Alon","year":"2017","journal-title":"Proc. Nat. Acad. Sci."},{"key":"10.1016\/j.schres.2019.08.029_bb0010","doi-asserted-by":"crossref","first-page":"280","DOI":"10.4088\/JCP.08m04250yel","article-title":"Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study","volume":"71","author":"Bobes","year":"2010","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2019.08.029_bb0015","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1176\/appi.ajp.2017.17010122","article-title":"Efficacy and safety of MIN-101: a new drug in development for the treatment of negative symptoms in schizophrenia: a 12-week randomized, double blind, placebo-controlled trial","volume":"174","author":"Davidson","year":"2017","journal-title":"Am.J. Psychiatry."},{"key":"10.1016\/j.schres.2019.08.029_bb0020","first-page":"18","article-title":"Using the Positive and Negative Syndrome Scale (PANSS) to define different domains of negative symptoms: prediction of everyday functioning by impairments in emotional expression and emotional experience","volume":"14","author":"Harvey","year":"2017","journal-title":"Innov. Clin. Neurosci."},{"key":"10.1016\/j.schres.2019.08.029_bb0025","doi-asserted-by":"crossref","unstructured":"Harvey, P,.D., Deckler. E., Jarskog, L.F., Penn, D.L., Pinkham, A.E. 2019. Predictors of social functioning in patients with higher and lower levels of reduced emotional experience: social cognition, social competence, and symptom severity. Schizophr. Res.206:271\u2013276.","DOI":"10.1016\/j.schres.2018.11.005"},{"key":"10.1016\/j.schres.2019.08.029_bb0030","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2174\/157015905774322516","article-title":"The sigma receptor: evolution of the concept in neuropsychopharmacology","volume":"3","author":"Hayashi","year":"2005","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.schres.2019.08.029_bb0035","doi-asserted-by":"crossref","first-page":"880","DOI":"10.3390\/ph4060880","article-title":"A role for sigma receptors in stimulant self administration and addiction","volume":"4","author":"Katz","year":"2011","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.schres.2019.08.029_bb0040","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2019.08.029_bb0045","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/biomet\/90.1.53","article-title":"Pattern-mixture models with proper time dependence","volume":"90","author":"Kenward","year":"2003","journal-title":"Biometrika"},{"key":"10.1016\/j.schres.2019.08.029_bb0050","first-page":"30","article-title":"Negative symptom dimensions of the positive and negative syndrome scale across geographical regions: implications for social, linguistic, and cultural consistency","volume":"14","author":"Khan","year":"2017","journal-title":"Innov. Clin. Neurosci."},{"key":"10.1016\/j.schres.2019.08.029_bb0055","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/schbul\/sbj053","article-title":"The NIMH-MATRICS consensus statement on negative symptoms","volume":"32","author":"Kirkpatrick","year":"2006","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2019.08.029_bb0060","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.schres.2017.11.031","article-title":"The brief negative symptom scale (BNSS): sensitivity to treatment effects","volume":"197","author":"Kirkpatrick","year":"2018","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2019.08.029_bb0065","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/syn.21717","article-title":"A selective sigma-2 receptor ligand antagonizes cocaine-induced hyperlocomotion in mice","volume":"68","author":"Lever","year":"2014","journal-title":"Synapse"},{"key":"10.1016\/j.schres.2019.08.029_bb0070","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.euroneuro.2013.10.018","article-title":"Negative symptoms, past and present: a historical perspective and moving to DSM-5","volume":"24","author":"Malaspina","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2019.08.029_bb0075","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1176\/ajp.151.6.825","article-title":"Risperidone in the treatment of schizophrenia","volume":"151","author":"Marder","year":"1994","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2019.08.029_bb0080","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.euroneuro.2014.03.008","article-title":"Negative symptoms of schizophrenia: clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment","volume":"24","author":"Millan","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2019.08.029_bb0085","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.schres.2013.07.014","article-title":"Association of prominent positive and prominent negative symptoms and functional health, well-being, healthcare-related quality of life and family burden: a CATIE analysis","volume":"150","author":"Rabinowitz","year":"2013","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2019.08.029_bb0090","doi-asserted-by":"crossref","first-page":"863","DOI":"10.2174\/138161212799436458","article-title":"Pharmacology of sigma (s) receptor ligands from a behavioral perspective","volume":"18","author":"Skuza","year":"2012","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.schres.2019.08.029_bb0095","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jpsychires.2018.06.018","article-title":"Which levels of cognitive impairments and negative symptoms are related to functional deficits in schizophrenia?","volume":"104","author":"Strassnig","year":"2018","journal-title":"J. Psychiatr. Res."},{"issue":"47","key":"10.1016\/j.schres.2019.08.029_bb0100","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.jpsychires.2013.01.015","article-title":"Deconstructing negative symptoms of schizophrenia: avolition-apathy and diminished expression clusters predict clinical presentation and functional outcome","volume":"2013","author":"Strauss","year":"2013","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.schres.2019.08.029_bb0105","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.schres.2014.10.043","article-title":"Negative symptoms and functioning during the first year after a recent onset of schizophrenia and 8 years later","volume":"161","author":"Ventura","year":"2015","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2019.08.029_bb0110","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/S0022-3565(24)35369-8","article-title":"Modulation of cellular calcium by sigma-2 receptors: release from intracellular stores in human SK-N-SH neuroblastoma cells","volume":"292","author":"Vilner","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.schres.2019.08.029_bb0115","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1159\/000285058","article-title":"Empirical assessment of the factorial structure of clinical symptoms in schizophrenia","volume":"30","author":"White","year":"1997","journal-title":"Psychopathology"}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996419303858?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996419303858?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:34:07Z","timestamp":1760297647000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996419303858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":23,"alternative-id":["S0920996419303858"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2019.08.029","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of Roluperidone (MIN-101) on two dimensions of the negative symptoms factor score: Reduced emotional experience and reduced emotional expression","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2019.08.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}